JP2010526068A5 - - Google Patents

Download PDF

Info

Publication number
JP2010526068A5
JP2010526068A5 JP2010506314A JP2010506314A JP2010526068A5 JP 2010526068 A5 JP2010526068 A5 JP 2010526068A5 JP 2010506314 A JP2010506314 A JP 2010506314A JP 2010506314 A JP2010506314 A JP 2010506314A JP 2010526068 A5 JP2010526068 A5 JP 2010526068A5
Authority
JP
Japan
Prior art keywords
itpp
composition
inositol
tripyrophosphate
erythropoietin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010506314A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010526068A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/005603 external-priority patent/WO2008134082A1/en
Publication of JP2010526068A publication Critical patent/JP2010526068A/ja
Publication of JP2010526068A5 publication Critical patent/JP2010526068A5/ja
Pending legal-status Critical Current

Links

JP2010506314A 2007-05-01 2008-05-01 エリスロポエチン補完または置換 Pending JP2010526068A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92705907P 2007-05-01 2007-05-01
PCT/US2008/005603 WO2008134082A1 (en) 2007-05-01 2008-05-01 Erythropoietin complementation or replacement

Publications (2)

Publication Number Publication Date
JP2010526068A JP2010526068A (ja) 2010-07-29
JP2010526068A5 true JP2010526068A5 (enExample) 2012-07-12

Family

ID=39926016

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010506314A Pending JP2010526068A (ja) 2007-05-01 2008-05-01 エリスロポエチン補完または置換

Country Status (7)

Country Link
US (2) US20080312138A1 (enExample)
EP (1) EP2152085A4 (enExample)
JP (1) JP2010526068A (enExample)
CN (1) CN101784193A (enExample)
AU (1) AU2008246061A1 (enExample)
CA (1) CA2688233A1 (enExample)
WO (1) WO2008134082A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130266668A1 (en) * 2010-12-01 2013-10-10 Virginia Commonwealth University Use of hemoglobin effectors to increase the bioavailability of therapeutic gases
US10159688B2 (en) 2013-03-15 2018-12-25 M. Alphabet 3, L.L.C. Methods and compositions for enhancing oxygen levels in tissues
WO2015138916A1 (en) * 2014-03-14 2015-09-17 Yves Claude Nicolau Myo-inositol trispyrophoshate as an anti-diabetic agent
CN111714504A (zh) * 2020-06-08 2020-09-29 广州新民培林医药科技有限公司 Itpp在制备预防和/或治疗缺血缺氧损伤及肺损伤的药物中的应用

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2740053A1 (de) * 1977-09-06 1979-05-03 Klaus Prof Dr Med Gersonde Verwendung von allosterischen effektoren mit hilfe von lipidvesikeln ueber eine irreversible inkorporierung zwecks verbesserter o tief 2 -entladung des haemoglobins in erythrozyten
US4192869A (en) * 1977-09-06 1980-03-11 Studiengesellschaft Kohle Mbh. Controlled improvement of the O2 release by intact erythrocytes with lipid vesicles
JPS5828878B2 (ja) * 1980-08-20 1983-06-18 三金工業株式会社 環状ピロ燐酸エステル誘導体
US4473496A (en) * 1981-09-14 1984-09-25 The United States Of America As Represented By The Secretary Of The Army Intramolecularly crosslinked hemoglobin
FR2529463B1 (fr) * 1982-07-05 1986-01-10 Centre Nat Rech Scient Procede et dispositif pour l'encapsulation dans les erythrocytes d'au moins une substance a activite biologique, notamment des effecteurs allosteriques de l'hemoglobine et erythrocytes ainsi obtenus
US4478824A (en) * 1983-08-08 1984-10-23 Franco Robert S Method for altering red blood cell function and survival
GB8328917D0 (en) * 1983-10-28 1983-11-30 Fisons Plc Blood substitute
SE465951B (sv) * 1984-10-23 1991-11-25 Perstorp Ab Isomer av inositoltrifosfat foeretraedesvis i saltform foer anvaendning som terapeutiskt eller profylaktiskt medel samt kompositioner daerav
US5330979A (en) * 1984-10-23 1994-07-19 Perstorp Ab Method of treating renal disorders with inositoltriphosphate
US5545632A (en) * 1984-10-23 1996-08-13 Perstorp Ab Method of treating retroviral disease
US5015634A (en) * 1986-04-16 1991-05-14 Perstorp Ab Method of treating tissue damage with inositol triphosphate
US5023248A (en) * 1984-10-23 1991-06-11 Perstorp Ab Method of treating diabetes with inositol triphosphate
US5407924A (en) * 1984-10-23 1995-04-18 Perstorp Ab Method of treating pain using inositol triphosphate
SE465305B (sv) * 1986-04-16 1991-08-26 Perstorp Ab Anvaendning av inositolfosfat foer framstaellning av ett laekemedel
US4887995A (en) * 1985-01-22 1989-12-19 University Of Pittsburgh Method of treating sickle cell anemia
WO1987005598A1 (fr) * 1986-03-11 1987-09-24 Mitsui Toatsu Chemicals, Incorporated Derives de myoinositol et procede de preparation
US5292913A (en) * 1986-03-11 1994-03-08 Mitsui Toatsu Chemicals, Incorporated Myoinositol derivatives and preparation process thereof
US4751244A (en) * 1986-04-04 1988-06-14 Merck & Co., Inc. Compounds useful in treating sickle cell anemia
US4731473A (en) * 1986-04-04 1988-03-15 Merck & Co., Inc. Compounds useful in treating sickle cell anemia
US4731381A (en) * 1986-04-04 1988-03-15 Merck & Co., Inc. Method of treating a person for sickle cell anemia
US4699926A (en) * 1986-04-04 1987-10-13 Merck & Co., Inc. Compounds useful in treating sickle cell anemia
US5135923A (en) * 1986-04-16 1992-08-04 Perstorp Ab Method of treating cardiovascular diseases
US5057507A (en) * 1986-04-16 1991-10-15 Perstorp Ab Method of alleviating bone damage with inositoltriphosphate
US5274161A (en) * 1986-11-26 1993-12-28 Perstorp Ab Derivatives of cyclohexane
US4847082A (en) * 1987-01-21 1989-07-11 Robert Sabin Method of treatment of Alzheimer's disease using phytic acid
US4873355A (en) * 1987-05-29 1989-10-10 E. I. Du Pont De Nemours And Company Process for regioselectively preparing phosphorylated inositols and other cyclitols
US4924023A (en) * 1987-05-29 1990-05-08 E. I. Du Pont De Nemours And Company Phosphorylated inositols
US4931276A (en) * 1987-10-30 1990-06-05 Franco Robert S Method for introducing desired agents into red blood cells
US4826675A (en) * 1988-02-17 1989-05-02 Colgate-Palmolive Company Anticalculus oral composition
US5043261A (en) * 1989-04-10 1991-08-27 Cryopharm Corporation Lyophilized and reconstituted red blood cell and hemosome compositions
US5082833A (en) * 1988-06-30 1992-01-21 Shamsuddin Abulkalam M Reduction of cell proliferation and enhancement of nk-cell activity
US4874690A (en) * 1988-08-26 1989-10-17 Cryopharm Corporation Lyophilization of red blood cells
US5264605A (en) * 1989-06-28 1993-11-23 Mitsui Toatsu Chemicals, Incorporated Myoinsitol derivatives, process for preparing same, phosphorylating agent, and its utilization
US5151539A (en) * 1989-07-03 1992-09-29 Akzo America Inc. Formation of tetraarylpyrophosphate
WO1991004258A1 (fr) * 1989-09-22 1991-04-04 Mitsui Toatsu Chemicals, Incorporated Derive d'ionisotol et production de ce derive
JPH03115290A (ja) * 1989-09-28 1991-05-16 Yokohama Rubber Co Ltd:The １ｄ―ミオイノシトール―１―リン酸の合成法
US5173426A (en) * 1989-10-06 1992-12-22 Yale University DNAs encoding genetically engineered low oxygen affinity mutants of human hemoglobin
US5210263A (en) * 1990-05-15 1993-05-11 University Of Pittsburgh Inositol phosphate analogs and methods for their use
US5295944A (en) * 1991-05-14 1994-03-22 Dana-Farber Cancer Institute Method for treating a tumor with ionizing radiation
US5260472A (en) * 1992-01-29 1993-11-09 The Board Of Governors For Higher Education State Of Rhode Island And Providence Plantations Efficient chemoenzymatic synthesis of D-myo-inositol 1,4,5-triphosphate, D-myo-inositol 1,3,4-triphosphate, and D-myo-inositol 1,3,4,5-tetraphosphate
US5296466A (en) * 1992-02-19 1994-03-22 Board Of Regents, The University Of Texas System Inhibition of nitric oxide-mediated hypotension and septic shock with iron-containing hemoprotein
US5344393A (en) * 1992-02-28 1994-09-06 Alliance Pharmaceutical Corp. Use of synthetic oxygen carriers to facilitate oxygen delivery
US5260287A (en) * 1992-05-11 1993-11-09 Board Of Regents, The University Of Texas System Polyphosphorylated organic compounds: compositions useful in protecting biological tissues
EP0690671B1 (en) * 1993-03-23 2004-08-04 Cbr Laboratories, Inc. Method and apparatus for encapsulation of biologically-active substances in cells
US5866548A (en) * 1993-04-09 1999-02-02 The Regents Of The University Of California Caged membrane-permeant inositol phosphates
US5827837A (en) * 1993-08-20 1998-10-27 The Regents Of The University Of California Polyanion anti-inflammatory agents
SE502989C2 (sv) * 1993-11-22 1996-03-04 Perstorp Ab Användning av en inositoltrisfosfatester för beredning av läkemedel
SE503122C2 (sv) * 1993-11-22 1996-03-25 Perstorp Ab Användning av en inositoltrisfosfatester för behandling av inflammatoriska tillstånd
US5720921A (en) * 1995-03-10 1998-02-24 Entremed, Inc. Flow electroporation chamber and method
US6074605A (en) * 1995-03-10 2000-06-13 Entremed, Inc. Flow electroporation chamber and method
US5626884A (en) * 1995-08-18 1997-05-06 Lockett; Curtis G. Treatment of sickle cell disease
US6949517B1 (en) * 1996-06-24 2005-09-27 Matti Siren Method of treating inflammatory, tissue repair and infectious conditions
US5880099A (en) * 1996-09-20 1999-03-09 The Regents Of The University Of California Inositol polyphosphates and methods of using same
US5977078A (en) * 1996-09-20 1999-11-02 The Regents Of The Univesity Of California Inositol polyphosphate derivatives and methods of using same
DE19649350A1 (de) * 1996-11-28 1998-06-04 Hoechst Ag Inositolglykane mit insulinartiger Wirkung
US6096916A (en) * 1997-05-23 2000-08-01 Nutrimed Biotech Synthesis of D-3 phosphorylated phosphoinositides and analogues
US6187335B1 (en) * 1997-12-31 2001-02-13 Orasomal Technologies, Inc. Polymerizable fatty acids, phospholipids and polymerized liposomes therefrom
US7309687B1 (en) * 1999-04-13 2007-12-18 The Kenneth S. Warren Institute, Inc. Methods for treatment and prevention of neuromuscular and muscular conditions by peripherally administered erythropoietin
EP1272201B1 (de) * 2000-04-12 2004-11-24 Bitop Aktiengesellschaft Für Biotechnische Optimierung Verwendung von kompatiblen soluten als substanzen mit radikalfangenden eigenschaften
US7084126B1 (en) * 2000-05-01 2006-08-01 Healthpartners Research Foundation Methods and compositions for enhancing cellular function through protection of tissue components
WO2002009723A2 (en) * 2000-08-01 2002-02-07 Gmp Companies, Inc. Ammonium salts of hemoglobin allosteric effectors, and uses thereof
US6610702B2 (en) * 2000-08-01 2003-08-26 Gmp Oxycell, Inc. Ammonium salts of inositol hexaphosphate, and uses thereof
AU2002217808A1 (en) * 2000-11-21 2002-06-03 Inologic, Inc. Inositol derivatives for increasing chloride secretion and inhibiting inflammation
US7300916B2 (en) * 2001-02-27 2007-11-27 Yoshiko Yasuda Preventives/remedies for thickened scar, keloid or chronic arthritic diseases
EP1379275A4 (en) * 2001-03-14 2005-12-21 Centocor Inc IMMUNOGLOBULIN-ASSOCIATED PROTEINS ASSOCIATED WITH OBSTRUCTIVE CHRONIC BRONCHOPNEUMOPATHY, COMPOSITIONS, METHODS AND USES
AU2002327006A1 (en) * 2001-09-20 2003-04-01 Inologic, Inc. Method of modulating sodium ion absorption in epithelial cells
AU2003231157C1 (en) * 2002-04-29 2009-02-26 Normoxys, Inc. Inositol pyrophosphates, and methods of use thereof
WO2004002403A2 (en) * 2002-06-14 2004-01-08 Gmp Oxycell, Inc. Sterols bearing pendant allosteric effectors of hemoglobin, and uses thereof
US20050176627A1 (en) * 2002-09-09 2005-08-11 Anthony Cerami Long acting erythropoietins that maintain tissue protective activity of endogenous erythropoietin
CA2520291A1 (en) * 2003-03-27 2004-10-14 Inologic, Inc. Camphanylidene and phenylalkyl inositol polyphosphate compounds, compositions, and methods of their use
ES2232302B1 (es) * 2003-11-07 2006-08-01 Universitat De Les Illes Balears Myo-inositol hexafosfato para uso topico.
US20070135389A1 (en) * 2004-07-06 2007-06-14 Claude Nicolau Tumor eradication by inositol-tripyrophosphate
US20060258626A1 (en) * 2004-07-06 2006-11-16 Claude Nicolau Use of inositol-tripyrophosphate in treating tumors and diseases
US20060106000A1 (en) * 2004-07-06 2006-05-18 Claude Nicolau Use of inositol-tripyrophosphate in treating tumors and diseases
PL1863495T3 (pl) * 2005-03-18 2015-06-30 Normoxys Inc Sól wapniowa 1,6:2,3:4,5-tripirofosforanu mioinozytolu jako efektor allosteryczny hemoglobiny w leczeniu raka
CN101686986A (zh) * 2006-12-29 2010-03-31 诺尔姆奥克西斯公司 环多醇和其衍生物及其治疗应用

Similar Documents

Publication Publication Date Title
Rawal et al. Anemia in intensive care: a review of current concepts
Elliott et al. Hyporesponsiveness to erythropoietin: causes and management
JP2015535209A5 (enExample)
AU2011329088B2 (en) Methods for enhancing oxygenation of jeopardized tissue
Yeatman et al. Magnesium-supplemented warm blood cardioplegia in patients undergoing coronary artery revascularization
JP2018507260A5 (enExample)
JP2010526068A5 (enExample)
Diehl et al. Use of continuous renal replacement therapy for treatment of dogs and cats with acute or acute‐on‐chronic renal failure: 33 cases (2002–2006)
Asare Anemia of critical illness
Lee et al. Is there a relationship between hyperkalemia and propofol?
US20110294732A1 (en) Erythropoletin complementation or replacement
Vadehra et al. Treating a patient with your hands tied: acute chest syndrome in a Jehovah’s Witness
Schmid et al. New strategies for managing anemia of chronic kidney disease
Arıcan et al. Clinical comparison of medetomidine with isoflurane or sevoflurane for anesthesia in horses.
Nakamura et al. Polymyxin B–Immobilized Fiber Hemoperfusion With the PMX-05R Column in Elderly Patients Suffering From Septic Shock
CN101708184B (zh) 铁脂质体的药物应用
AU2014264537B2 (en) Dialysis formulation
Pereira et al. Near-fatal pulmonary embolism in an experimental model: hemodynamic, gasometric and capnographic variables
Fishbane et al. Roxadustat Lowers Risk of Red Blood Cell Transfusion in Patients with Anemia of CKD: PO0256
Kopparthy et al. Red blood cell exchange in a patient with extramedullary hematopoiesis and cor pulmonale secondary to beta thalassemia
CA2799624C (en) Dialysis and substitution fluid
He et al. High-risk end-stage renal disease patients converted from conventional to short daily haemodialysis
CN101568334A (zh) 铁代谢改善剂
Hoffman et al. Triferic (Ferric Pyrophosphate Citrate, FPC) Maintains Hemoglobin and Reduces IV Iron: Results from a Single-Site 2-Year Observational Analysis: PO0255
Ito et al. MO525: Iron absorption and phosphate-lowering effects of ferric citrate hydrate are not influenced by gastric secretion inhibitors in patients with chronic kidney disease